Ask The Recruiter

4D Molecular Therapeutics

Adding Roles, last update 1 week ago

Pharma biotech · Headquarters United States

Everything we hold on 4D Molecular Therapeutics, newest first. Every line links to the filing or report it came from.

5 updates tracked
1 leadership change
31 Dec 2023 tracked since
United States where
  1. 2026-08-12
    Adding Roles Growing and expanding

    4D Molecular Therapeutics opened 5 more roles in United States (job board: 10 to 15)

    A board that grows week on week is the earliest public evidence of hiring intent an employer produces: it moves before any announcement and before any filing. Treat the direction as the signal and the exact count as approximate, since roles are reposted, split across locations and withdrawn without notice.

    United States · 5 roles · News Report · Greenhouse job board · archived copy

  2. 2026-01-07
    Headcount Not Stated Leadership moves

    4D Molecular Therapeutics, Inc. 8-K filing (Item 5.02): officer or director change

    4D Molecular Therapeutics has a leadership change in Emeryville; the filing does not disclose hiring plans.

    United States · Official Filing · SEC EDGAR

  3. 2025-12-31
    Pay Change Pay and benefits

    4D MOLECULAR THERAPEUTICS, INC.: $2,051,343 total compensation for the principal executive officer, fiscal year ended 2025-12-31

    Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.

    United States · Official Filing · SEC EDGAR (pay-versus-performance)

  4. 2024-12-31
    Pay Change Pay and benefits

    4D MOLECULAR THERAPEUTICS, INC.: $1,009,004 total compensation for the principal executive officer, fiscal year ended 2024-12-31

    Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.

    United States · Official Filing · SEC EDGAR (pay-versus-performance)

  5. 2023-12-31
    Pay Change Pay and benefits

    4D MOLECULAR THERAPEUTICS, INC.: $10,286,808 total compensation for the principal executive officer, fiscal year ended 2023-12-31

    Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.

    United States · Official Filing · SEC EDGAR (pay-versus-performance)

Cite this page4D Molecular Therapeutics. Talent Intelligence Tracker, AskTheRecruiter.com. Accessed Aug 20, 2026. https://asktherecruiter.com/blog/talent-intelligence-tracker/company/4d-molecular-therapeutics/ Licensed CC BY 4.0; every record links to the document behind it.

The read-through on each line is our interpretation. The headline and figures come from the linked source. Data licensed CC BY 4.0. Back to the tracker